


Next generation platform enabling breakthroughs for cancer and other diseases

Technology / Capability Overview:

Breakthrough exosome technology that enables new ways to diagnose and treat diseases and exposures such as cancer, infection and brain injury.

- Use saliva, blood or other biofluid to diagnose diseases or exposures using exosomes.
- Provides a pure, active ingredient for therapeutic use of exosomes.
- Simple isolation protocol that can be used in any lab setting with minimal training.
- A platform that can be automated for high throughput.
- Unlocks the cell to cell communication system by providing access to specific exosomes.



Relevance to Combatant Command or other Need:

Category* : Force Protection & Medical

Clara Biotech's platform enables a number of technologies in the exciting field of exosomes. Our pure exosomes enable others to develop:

- Next generation cancer immunotherapies to train the immune system to fight cancer.
- Deliver gene therapies with no immune response.
- Deliver therapies across the blood brain barrier.
- Ability to regenerate organs and tissues.
- Ability to detect cancer, Alzheimer's Disease, traumatic brain injury (TBI), neural disorders and more from <1 mL blood.
- Improve transplant viability and outcomes.

Past Performance of Technology and Company:

- Exosome isolation lab service since 2019.
- SBIR Phase 1 from National Cancer Institute.
- Lab studies on uniquely detecting cancer (validated 2 cancer centers).
- Detects bladder cancer via urine in lab studies.
- Detects ovarian cancer via blood in lab studies.



Maturity / Scalability / Cost / Schedule

TRL : 7

Our device is currently a single-use consumable and a tool the size of a shoe box, allowing it to be placed in any lab setting. Ongoing BETA evaluation with paying customers (academic, diagnostics, drug development).

SCALING CONSIDERATIONS:

Currently validating and scaling our manufacturing processes to support market launch. Future: Automated sample processing.

TIME TO MARKET WITH CURRENT FINANCIAL PLANS:

We plan to launch our first product by the end of 2021.

TIME TO MARKET WITH FINANCIAL ASSISTANCE:

With financial assistance we could work to scale our manufacturing and automation to support clinical use of our technology.

Website: www.EncounteringInnovation.com

Email: EIAdmin@ksbdc.net

* Relative to Combatant Command Common Capability Needs Chart at:

<https://defenseinnovationmarketplace.dtic.mil/wp-content/uploads/2020/02/CCMC-Common-Capability-Needs-Feb-2020.pdf>